BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jomard A, Osto E. High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential. Front Cardiovasc Med 2020;7:39. [PMID: 32296714 DOI: 10.3389/fcvm.2020.00039] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Jones PR, Rajalahti T, Resaland GK, Aadland E, Steene-johannessen J, Anderssen SA, Bathen TF, Andreassen T, Kvalheim OM, Ekelund U. Associations of lipoprotein particle profile and objectively measured physical activity and sedentary time in schoolchildren: a prospective cohort study. Int J Behav Nutr Phys Act 2022;19. [DOI: 10.1186/s12966-022-01244-w] [Reference Citation Analysis]
2 Sun L, Duan L, Jia D. Clinical characteristics of cardiovascular patients with extremely low levels of high-density lipoprotein cholesterol. Lipids Health Dis 2021;20:149. [PMID: 34717644 DOI: 10.1186/s12944-021-01583-w] [Reference Citation Analysis]
3 Martinez LO, Ingueneau C, Genoux A. Is it time to reconcile HDL with cardiovascular diseases and beyond? An update on a paradigm shift. Current Opinion in Lipidology 2020;31:302-4. [DOI: 10.1097/mol.0000000000000705] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Liao J, Bai J, An X, Liu Y, Wang Y, Liu G, Huang W, Xia Y. Lipoprotein Glomerulopathy-Like Lesions in Atherosclerotic Mice Defected With HDL Receptor SR-B1. Front Cardiovasc Med 2021;8:734824. [PMID: 34692787 DOI: 10.3389/fcvm.2021.734824] [Reference Citation Analysis]
5 Marsillach J, Adorni MP, Zimetti F, Papotti B, Zuliani G, Cervellati C. HDL Proteome and Alzheimer's Disease: Evidence of a Link. Antioxidants (Basel) 2020;9:E1224. [PMID: 33287338 DOI: 10.3390/antiox9121224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 He H, Hong K, Liu L, Schwendeman A. Artificial high-density lipoprotein-mimicking nanotherapeutics for the treatment of cardiovascular diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1737. [PMID: 34263549 DOI: 10.1002/wnan.1737] [Reference Citation Analysis]
7 Gundacker C, Forsthuber M, Szigeti T, Kakucs R, Mustieles V, Fernandez MF, Bengtsen E, Vogel U, Hougaard KS, Saber AT. Lead (Pb) and neurodevelopment: A review on exposure and biomarkers of effect (BDNF, HDL) and susceptibility. Int J Hyg Environ Health 2021;238:113855. [PMID: 34655857 DOI: 10.1016/j.ijheh.2021.113855] [Reference Citation Analysis]
8 Kudinov VA, Alekseeva OY, Torkhovskaya TI, Baskaev KK, Artyushev RI, Saburina IN, Markin SS. High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma. Int J Mol Sci 2020;21:E8737. [PMID: 33228032 DOI: 10.3390/ijms21228737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Miura K, Arai N, Goka R, Morimoto N, Watanabe S, Isoda N, Yamamoto H, Kotani K. Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease. Antioxidants (Basel) 2021;10:239. [PMID: 33557304 DOI: 10.3390/antiox10020239] [Reference Citation Analysis]
10 Romagnoli T, Ortolani B, Sanz JM, Trentini A, Seripa D, Nora ED, Capatti E, Cervellati C, Passaro A, Zuliani G, Brombo G. Serum Apo J as a potential marker of conversion from mild cognitive impairment to dementia. J Neurol Sci 2021;427:117537. [PMID: 34147956 DOI: 10.1016/j.jns.2021.117537] [Reference Citation Analysis]
11 Kluck GEG, Yoo JA, Sakarya EH, Trigatti BL. Good Cholesterol Gone Bad? HDL and COVID-19. Int J Mol Sci 2021;22:10182. [PMID: 34638523 DOI: 10.3390/ijms221910182] [Reference Citation Analysis]
12 Kjeldsen EW, Thomassen JQ, Juul Rasmussen I, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R. Plasma HDL cholesterol and risk of dementia - observational and genetic studies. Cardiovasc Res 2021:cvab164. [PMID: 33964140 DOI: 10.1093/cvr/cvab164] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Zuin M, Cervellati C, Trentini A, Passaro A, Rosta V, Zimetti F, Zuliani G. Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer's Disease: Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:984. [PMID: 34071695 DOI: 10.3390/diagnostics11060984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Khan AA, Kim N, Korstanje R, Choi S. Loss-of-function mutation in Pcsk1 increases serum APOA1 level and LCAT activity in mice. Lab Anim Res 2022;38:1. [PMID: 34996527 DOI: 10.1186/s42826-021-00111-2] [Reference Citation Analysis]